Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of diseases with high unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of RNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of RNA medicines.
March 27, 2020
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
March 11, 2020
Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results
March 4, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology